Wegovy Dosage Guide: The Complete Schedule from 0.25mg to 2.4mg

Most people starting Wegovy get handed a prescription and a pamphlet. The pamphlet tells them to inject 0.25mg once a week. What it doesn't explain is why the dose escalates so slowly, what happens if they can't tolerate the next step up, or why only 13% of real-world users ever reach the maximum dose.

This is the guide that fills in those gaps. We'll walk through the full dosage schedule, what the clinical data actually says about outcomes, and how to think about the side effects most people don't ask their doctor about directly.

---

What Is a GLP-1 and How Does Wegovy Work?

Wegovy doesn't suppress your appetite the way a stimulant does. It amplifies a signal your body already produces, one that tells your brain you've eaten enough. That signal is GLP-1.

GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut releases after you eat. It tells your pancreas to release insulin, tells your liver to stop dumping glucose into your blood, and, most relevant to weight loss, signals your brain that you're full.

Semaglutide, the active ingredient in Wegovy, is a synthetic version of that hormone engineered to last about a week in your system instead of a few minutes. When you inject it, you're turning up the volume on a signal your body already produces (Mahapatra et al., 2022).

The result isn't willpower in a syringe. It's more like the food noise that lives in the back of your head — the constant low-grade preoccupation with what you're going to eat next — goes quiet. People who've been on it for months consistently describe it as "turning the volume down" rather than "flipping a switch."

That brain-level effect is why GLP-1 medications have become a different category of treatment than anything that came before them.

---

The FDA-Approved Wegovy Dosage Schedule

Wegovy (semaglutide 2.4mg) was FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia).

The escalation schedule is not optional. It's designed specifically to let your GI system adapt, which is the main reason people discontinue.

Week	Dose	What's Happening
Weeks 1–4	0.25mg	Initiation, not a therapeutic dose
Weeks 5–8	0.5mg	Still building tolerance
Weeks 9–12	1.0mg	First therapeutic threshold
Weeks 13–16	1.7mg	Required minimum for maintenance
Week 17+	2.4mg	Target maintenance dose

The 0.25mg starting dose is explicitly described in prescribing information as an initiation dose. It is not effective for weight loss on its own. This matters because some physicians, particularly those unfamiliar with the titration rationale, have been keeping patients at 0.25mg indefinitely (r/pharmacy, 2024). That's a waste of the medication and the patient's time.

The FDA label updated in late 2025 added new warnings around acute pancreatitis, acute kidney injury from volume depletion, and severe GI adverse reactions — worth knowing if you're starting.

---

What to Expect Week by Week: A Practical Timeline

Weeks 1–4 (0.25mg). Don't expect visible weight changes yet. Your body is adjusting to the medication. Mild nausea is common. The goal is tolerability, not results.

Weeks 5–12 (0.5mg–1.0mg). Most people notice appetite changes here — smaller portion sizes feel satisfying and food cravings become less intense. Weight loss typically begins in this window.

Weeks 13–16 (1.7mg). The Wegovy label explicitly states: if you cannot tolerate 1.7mg, discontinue. This isn't a failure. It's the medication not being the right tool for your body at that dose.

Week 17+ (2.4mg). Target maintenance. The pace of weight loss may slow compared to earlier weeks. This is normal and expected.

Months 4–12. The STEP 1 trial showed most weight loss occurring in the first 20 weeks, with a plateau after that. Don't interpret a plateau as the medication failing. It's the expected trajectory. Plateaus often respond to nutrition adjustments, not dose increases.

---

What Real-World Dosing Actually Looks Like

Here's the gap between clinical trial protocols and real life.

A 2024 Danish cohort study following 110,748 Wegovy users found that only 13% reached the 2.4mg maintenance dose by their fifth prescription (Ladebo et al., 2024). About 33–48% of users stayed at the 1.0mg dose from the fourth prescription onward. Just 10% followed the recommended dose escalation every 4 weeks.

That's not a failure. It's an important data point.

Many providers, and many patients, find that staying at a lower dose produces adequate results with fewer side effects. The real-world evidence suggests the trial's strict titration schedule doesn't translate to clinical practice, and for a lot of people, it doesn't need to.

What this means for you: the 2.4mg target is a ceiling, not a requirement. Your dose should be determined by your response, your tolerance, and your provider's assessment of your labs and progress.

---

How Much Weight Do People Actually Lose?

The STEP 1 trial, the pivotal phase 3 study that led to Wegovy's approval, enrolled 1,961 adults with obesity and no diabetes. At 68 weeks on 2.4mg semaglutide, participants lost an average of 14.9% of body weight versus 2.4% in the placebo group (Wilding et al., 2021).

Put that in real numbers: if you start at 200 pounds, 14.9% is about 30 pounds. That's a meaningful clinical result. For comparison, behavioral interventions typically produce 3–5% weight loss over the same period.

But there's a range in the data worth knowing. About 32% of participants in STEP 1 lost more than 20% of their body weight — roughly 40 pounds if you start at 200. Another subset lost less than 5%. Individual response varies considerably, and baseline characteristics (starting BMI, comorbidities, diet quality, activity level) all influence outcomes.

The OASIS 1 trial specifically studied oral semaglutide for obesity — the tablet formulation — and showed a 15.1% weight reduction over 68 weeks, comparable to the injectable (NCT05035095). The route of administration matters less than the drug itself.

---

Using the Wegovy Pen: What You Need to Know

Most people get their first pen and figure it out from the package insert. That works, but knowing a few things in advance saves confusion.

How many doses are in each pen. Each Wegovy pen contains four doses (one month of weekly injections). When you escalate to a new dose level, you start a new pen at the new strength. You don't adjust the dial on an existing pen. Each pen is preset to its dose, so there's no dial to change. If you're using the 0.25mg pen, you get four 0.25mg injections. Move to the next dose — you get a new pen.

Where to inject. The three approved injection sites are the abdomen (at least two inches from your navel), the outer thigh, and the upper arm. Rotate sites weekly. Injecting repeatedly in the same spot can cause lipohypertrophy, a buildup of fatty tissue under the skin that affects absorption. Abdomen tends to be the most accessible for self-injection.

Storage. Wegovy pens should be stored in the refrigerator at 36–46°F before first use. After first use, you can keep the pen at room temperature (up to 77°F) for up to 28 days, or refrigerate it. Never freeze. Keep it out of direct sunlight.

Dropped or damaged pen. If you drop a pen before first use, inspect it for damage. If the solution appears cloudy, discolored, or contains particles, don't use it. If a pen is damaged after first use, contact Novo Nordisk or your pharmacy. Don't attempt to use a pen that's been physically compromised.

Pen cap and needle handling. Always attach a new needle before each injection. Remove the needle immediately after injecting and dispose in a sharps container. Never share a pen. The pen itself, even with a new needle, should never be used by another person.

---

Side Effects: The Honest Breakdown

The most common side effects are GI: nausea, vomiting, diarrhea, constipation. These are dose-dependent, meaning they're worse during escalation and typically improve once you stabilize at a given dose.

In FAERS data from the FDA, 78,284 adverse event reports have been filed for semaglutide. The most frequently reported: fatigue, nausea, diarrhea, and shortness of breath (FDA FAERS, 2026). That's not a small number, but it's also a drug that millions of people take — context matters.

The side effects people ask about but don't always get straight answers on:

Nausea. It peaks in the first 4–8 weeks and during each dose escalation. Eating smaller portions, avoiding high-fat meals, and injecting at night (so you sleep through the worst of it) all help. It doesn't mean the medication isn't working. It's the mechanism.

Muscle loss. GLP-1 medications cause weight loss from both fat and lean mass. A 2026 study currently recruiting is specifically investigating changes in muscle mass and physical function with GLP-1 drugs (NCT07156331). The practical implication now: resistance training and adequate protein (1.6–2.2g/kg body weight) during treatment preserves lean mass more effectively than caloric restriction alone.

Hair thinning. Telogen effluvium, temporary hair shedding triggered by rapid weight loss and caloric restriction, affects a meaningful percentage of patients. This is not specific to semaglutide; it happens with any significant weight loss. It's usually temporary and resolves within 6–9 months.

"Ozempic face." The facial volume loss that comes with significant weight loss is real. It's not specific to semaglutide. It's a consequence of losing fat throughout your body, including your face. Learn more about what causes this and what options exist.

Eye changes. A 2025 FAERS analysis found 1,733 eye-related adverse event reports associated with semaglutide across formulations, with most occurring within the first month (Zhao et al., 2025). If you have diabetic retinopathy or another pre-existing eye condition, discuss this specifically with your provider before starting.

---

Contraindications: When Wegovy Isn't the Right Call

Not everyone is a candidate, and for some people, starting without this conversation could be genuinely dangerous. The FDA label carries a boxed warning for thyroid C-cell tumors, the most serious category of FDA warning. Here's who shouldn't use it and who should discuss it carefully before starting.

Wegovy is contraindicated in:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of serious hypersensitivity reactions to semaglutide
• Pregnancy

If any of the above apply, Wegovy is off the table. These aren't relative risks to weigh — they're hard stops.

Use with caution or discuss carefully if you have:

• History of pancreatitis
• Gallbladder disease or history of gallstones
• Diabetic retinopathy
• Chronic kidney disease (there are now specific dosing considerations)
• Heart rate or cardiac conduction issues

This second list is different. It's not an automatic no, but it means the conversation with your provider needs to be specific. Gallbladder disease and pancreatitis in particular deserve a full history review before starting. Semaglutide has shown cardiovascular benefits in patients with established cardiovascular disease (Mahapatra et al., 2022), but the decision to start requires a full clinical picture, not just a BMI cutoff.

---

GLP-1 Dosing and Fatty Liver

One area where the data is genuinely promising: semaglutide's effect on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Liver disease and obesity are tightly linked. Excess fat drives insulin resistance, and insulin resistance drives fat accumulation in the liver, a self-reinforcing loop. Semaglutide interrupts that loop from two directions: by reducing body weight and by directly reducing hepatic fat through its effect on glucagon signaling (Mahapatra et al., 2022).

Multiple clinical trials are currently investigating semaglutide specifically for liver disease outcomes, including preventing post-transplant NAFLD development (NCT05424003). Phase 2 data has shown meaningful reductions in liver fat, inflammation markers, and fibrosis scores in NASH patients. Phase 3 results are still emerging, but the signal is strong enough that liver disease is increasingly factored into GLP-1 prescribing decisions, not just as an afterthought, but as a primary indication for some patients.

If fatty liver disease is part of your picture, this is worth raising explicitly with your provider when discussing GLP-1 therapy. The weight-loss effect alone helps. But the direct hepatoprotective mechanism may make semaglutide a particularly useful tool if NAFLD or early NASH is in your labs.

---

The Role of Diet and Exercise on Wegovy

Wegovy's label, and the clinical trials, specify it as an adjunct to reduced-calorie diet and increased physical activity. It is not a standalone solution.

What the research shows: patients who combine GLP-1 therapy with structured nutrition support lose more weight and maintain it more effectively than those who rely on medication alone (Polonsky et al., 2021). The community data backs this up. The most successful long-term users consistently report working with a dietitian alongside their GLP-1 therapy.

If you're unsure where to start nutritionally, working with a registered dietitian who understands GLP-1 pharmacology is a different conversation than general diet advice.

Resistance training during treatment also protects against the lean mass loss that accompanies rapid weight reduction. This matters particularly if you start Wegovy with a low muscle mass baseline or if you're over 50.

---

Wegovy vs. Zepbound: Which One Is Right for You?

Patients ask this constantly, and the honest answer is: tirzepatide (Zepbound/Mounjaro) shows greater average weight loss in head-to-head comparisons.

The SURMOUNT and related trials showed tirzepatide at the 15mg dose producing weight loss in the 20–22% range, meaningfully higher than semaglutide's 15%. This is because tirzepatide hits two appetite-regulating pathways (GLP-1 and GIP) instead of one.

That said, individual response varies. Some patients who respond modestly to semaglutide do very well on tirzepatide, and vice versa. The GI side effect profiles are similar. Cost and insurance coverage differ by person and plan.

For a full comparison of available GLP-1 medications, including liraglutide, semaglutide, and tirzepatide, see our GLP-1 Medications Compared breakdown.

---

Cost, Coverage, and Savings Programs

Wegovy's list price is approximately $1,349 per month without insurance — that's per pen, four doses, one month of treatment. The dose doesn't change the price much between levels, since each pen contains four weekly injections regardless.

Insurance coverage is inconsistent. Many commercial plans cover Wegovy for patients who meet FDA criteria (BMI 30+, or 27+ with a qualifying comorbidity), but prior authorization is almost universal. Medicare Part D has historically excluded obesity medications, though this is actively changing as of 2026. Medicaid coverage varies by state.

The Novo Nordisk savings card (WegovyHCP.com) currently offers eligible commercially insured patients Wegovy for as little as $25/month for up to 24 months. There are income and insurance eligibility requirements. Patients on government insurance programs don't qualify.

For patients without insurance or with denied coverage, compounded semaglutide was widely available through telehealth providers during the shortage period, but FDA has moved to restrict compounding as Novo Nordisk restores supply. Verify current availability with your provider.

At HEXIS, we work through the prior authorization process for patients who qualify, and we'll tell you upfront if the paperwork isn't worth the fight for your specific situation. Schedule a consultation to get a direct answer on what coverage looks like in your case.

---

What Happens When You Stop

This is probably the hardest thing to hear about Wegovy, but you should hear it before you start, not after.

The weight comes back.

A 2025 narrative review of randomized controlled trials found rapid weight regain after discontinuing GLP-1 receptor agonists or tirzepatide, regardless of how long the treatment lasted (Quarenghi et al., 2025). This pattern appeared consistently across studies — stop the medication, lose the metabolic benefits within months. In the STEP 1 extension study, patients who stopped semaglutide regained roughly two-thirds of the weight they'd lost within a year.

That's not a flaw in the drug. It reflects the nature of the condition being treated. Obesity has a neurological component; the brain's regulation of body weight doesn't reset when you lose weight. Discontinuing the medication returns you to the underlying physiology. The food noise comes back. The satiety signal fades.

This is genuinely difficult. It changes how you need to think about starting in the first place. Wegovy is most effective when treated as a long-term management tool, not a short-term fix. Some providers explore maintenance dosing at lower levels (1.0mg or 0.5mg) once target weight is achieved, though this isn't formally studied in controlled trials.

If cost or access is forcing a stop, work with your provider on a tapering plan and a transition strategy, not a cold stop.

---

Frequently Asked Questions

What's the starting dose for Wegovy?

0.25mg once weekly for the first four weeks. This is strictly an initiation dose. It's not intended to produce weight loss. It gives your GI system time to adapt before moving to the therapeutic range.

Can I stay at a lower Wegovy dose if the side effects are too bad?

Yes. Real-world data shows that about one-third of users stabilize at 1.0mg rather than escalating to 2.4mg (Ladebo et al., 2024). If side effects are limiting, your provider can keep you at a lower dose, slow the titration schedule, or skip a dose step. The FDA label specifies that if you can't tolerate 1.7mg, the medication should be discontinued, but many patients find a workable dose below the maximum target.

What happens if I miss a Wegovy injection?

If you miss a dose and your next scheduled dose is more than 2 days away, take it as soon as you remember. If it's within 2 days of your next scheduled dose, skip the missed one and resume your regular schedule. Do not double up.

How long does it take for Wegovy to start working?

Most people notice appetite changes within the first 4–8 weeks, typically once they hit 0.5mg or 1.0mg. Measurable weight loss usually appears by weeks 8–12. Expecting results at the 0.25mg initiation phase sets up unrealistic benchmarks.

Will Wegovy work if I have type 2 diabetes?

Yes, but the formulation is different. Semaglutide for type 2 diabetes is FDA-approved as Ozempic at lower doses. Wegovy is the 2.4mg weight-management formulation. If you have T2D and want the weight-loss dose, your provider needs to prescribe Wegovy specifically. The PIONEER 3 trial demonstrated significant HbA1c reduction and weight loss in adults with type 2 diabetes uncontrolled on metformin (Rosenstock et al., 2019), so both goals are achievable, but the prescribing context differs.

How many doses are in a Wegovy pen?

Each Wegovy pen contains four doses — one month of weekly injections. The pens are preset to their dose level; there's no adjustment dial. When you move to the next dose in the escalation schedule, you receive a new pen at the higher strength.

Can I inject Wegovy somewhere other than my stomach?

Yes. The FDA-approved injection sites are the abdomen, outer thigh, and upper arm. Abdomen is most commonly used for self-injection. Rotate sites weekly. Injecting in the same location repeatedly can affect absorption and cause tissue changes under the skin.

How do I transition from Saxenda to Wegovy?

Saxenda (liraglutide) and Wegovy (semaglutide) are both GLP-1 receptor agonists but aren't interchangeable. When transitioning, most providers restart semaglutide titration from 0.25mg, even if you were at a high liraglutide dose. There's no standard washout period required between the two; your provider can typically start Wegovy the week after your last Saxenda dose. Expect some re-acclimation GI effects as your system adjusts to the new molecule.

What if I take too much Wegovy?

If you accidentally take a dose sooner than scheduled or inject twice, contact your provider or poison control. The most likely effects are intensified GI symptoms, nausea, vomiting, and diarrhea. Severe hypoglycemia is not expected in non-diabetic patients on Wegovy alone. Do not take an additional dose to "offset" the error. Document what happened and call your provider before your next scheduled dose.

Does Wegovy interact with other medications?

The primary interaction risk is with other medications that affect blood sugar, particularly insulin and sulfonylureas. If you're on either, your provider may need to adjust your diabetes medication doses to avoid hypoglycemia. Wegovy slows gastric emptying, which can affect the absorption timing of oral medications taken around the same time. If you take any time-sensitive oral medications (thyroid medications, oral contraceptives, blood thinners), discuss timing with your prescriber. Alcohol doesn't have a direct drug interaction but can worsen GI side effects and complicate blood sugar management.

What does the Wegovy pill look like compared to the injection?

The oral semaglutide formulation (brand name Rybelsus) is currently approved for type 2 diabetes, not for weight management. Wegovy is injection-only at 2.4mg. An oral obesity dose is under development. The OASIS 1 trial showed oral semaglutide producing 15.1% weight loss over 68 weeks (NCT05035095), comparable to the injectable, suggesting the delivery route may matter less than the drug itself when an oral obesity dose eventually reaches approval.

---

Starting with a Protocol, Not a Guess

The dosage schedule is the starting point. What determines how well Wegovy works for you is everything around it — your baseline labs, your metabolic picture, your nutritional approach, your body composition goals, and how your provider monitors and adjusts your protocol over time.

At HEXIS, we don't start people on weight management medications without labs. Your full metabolic panel, thyroid function, and relevant biomarkers tell us more about your individual response than any population average. If this is something you want to explore, we start with that picture, not a guess.

Schedule a consultation

---